UK markets close in 4 hours 33 minutes

Scholar Rock Holding Corporation (SRRK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.71-0.56 (-4.56%)
At close: 04:00PM EDT
11.62 -0.09 (-0.77%)
After hours: 06:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close12.27
Open12.19
Bid11.67 x 200
Ask11.70 x 100
Day's range11.65 - 12.77
52-week range5.56 - 21.17
Volume952,365
Avg. volume897,409
Market cap933.92M
Beta (5Y monthly)0.94
PE ratio (TTM)N/A
EPS (TTM)-2.09
Earnings date07 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est27.14
  • Business Wire

    Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

    CAMBRIDGE, Mass., May 22, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the initiation of the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, a highly selective myostatin inhibitor, to preserve lean muscle mass in indiv

  • Business Wire

    Scholar Rock to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., May 20, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in June:

  • Business Wire

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., May 17, 2024--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 102,150 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchas